The Biossil Leap: Can OpenAI's Bet Turn AI-First Biotech Into a Reality?
Toronto's Biossil hits unicorn status with a $1 billion valuation, signaling a high-stakes gamble on the intersection of generative AI and failed drug candidates.
Opinion: The Biossil Leap
As first reported by The Globe and Mail and detailed by BetaKit, Toronto-based Biossil has secured $153 million USD ($216 million CAD) in a financing round led by the OpenAI Startup Fund. The investment pushes the biotech firm's valuation to $1 billion USD.
Biossil operates on a rescue model: using an AI platform to identify molecules that failed original clinical trials and then buying or licensing those candidates to steer them toward success. This approach allows the startup to bypass the most expensive early stages of traditional drug discovery.
The involvement of OpenAI signals a broader trend of AI giants moving into physical medicine, echoed by Anthropic’s biolab in California and Cohere’s May acquisition of Reliant AI. Co-founder and CEO Anthony Mouchantaf noted on LinkedIn that translating AI insights into patient benefits requires dedicated infrastructure integrating AI and medicine from discovery through the clinic—infrastructure Biossil is currently building across Canada and the U.S.
Biossil is targeting challenging conditions, including Alzheimer’s, glioblastoma, breast cancer, idiopathic pulmonary fibrosis, and sickle cell disease. The all-equity round included backing from Founders Fund, Quiet Capital, Modern Capital, Golden Ventures, Panache Ventures, the Abu Dhabi Investment Council, and Duke University’s endowment fund.
From my perspective, Biossil is a win for Toronto, but the real test is whether their AI can predict regulatory approval better than original developers did. After emerging from stealth in April with $70 million USD, Biossil is now in the spotlight. If they can move these resurrected candidates through the clinic, they provide the blueprint for a new era of biotech.